Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study | Zendy

YueE Wu | Zendy; Tao Wang | Zendy; Hua-Liang Yang | Zendy; BoHao Tang | Zendy; Li Kong | Zendy; Xin Li | Zendy; Qi Gao | Zendy; Xue Li | Zendy; BuFan Yao | Zendy; HaiYan Shi | Zendy; Xin Huang | Zendy; Wenqi Wang | Zendy; Evelyne JacqzAigrain | Zendy; Karel Allegaert | Zendy; John van den Anker | Zendy; Xiuying Tian | Zendy; Wei Zhao | Zendy

Open Access

Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study

Author(s) -

YueE Wu,

Tao Wang,

Hua-Liang Yang,

BoHao Tang,

Li Kong,

Xin Li,

Qi Gao,

Xue Li,

BuFan Yao,

HaiYan Shi,

Xin Huang,

Wenqi Wang,

Evelyne JacqzAigrain,

Karel Allegaert,

John van den Anker,

Xiuying Tian,

Wei Zhao

Publication year - 2020

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkaa468

Subject(s) - azlocillin , dosing , pharmacokinetics , medicine , pharmacodynamics , population , regimen , adverse effect , pharmacology , nonmem , intensive care medicine , biology , genetics , environmental health , bacteria , pseudomonas aeruginosa , piperacillin

Nowadays, real-world data can be used to improve currently available dosing guidelines and to support regulatory approval of drugs for use in neonates by overcoming practical and ethical hurdles. This proof-of-concept study aimed to assess the population pharmacokinetics of azlocillin in neonates using real-world data, to make subsequent dose recommendations and to test these in neonates with early-onset sepsis (EOS).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research